Xiaomi flexes chip prowess as new XRing O1 bests Apple's A18 Pro in certain tests
Xiaomi on Thursday unveiled its new XRing O1 integrated circuit (IC) – designed to power the company's next-generation smartphones and tablets – that it claims bested the performance of Apple 's latest A18 Pro chip in certain benchmark tests.
'I have confidence to say that the XRing O1 is very strong,' Xiaomi founder, chairman and chief executive
Lei Jun said on Thursday at an event in
Beijing , where the firm's in-house-designed system-on-a-chip (SoC) was launched, alongside the 15S Pro smartphone and Pad 7 Ultra.
Lei attributed the XRing O1's performance to its system architecture and production using an advanced 3-nanometre lithography process, which enabled Xiaomi to pack 19 billion transistors on the SoC – a chip density on par with Apple's A18 series.
The XRing O1 features a so-called 10-core design, in which an IC has 10 individual processing units – or cores – capable of executing instructions.
At Thursday's event, Lei present data showing the XRing O1 matching Apple's A18 Pro chip in single-core and multi-core tests, and surpassing the US-designed chip 'by a large margin' in other benchmark tests.
The XRing O1's launch marked the culmination of Xiaomi's four-year-long journey to develop an advanced SoC that delivers top-tier performance, using Apple's A-series chips as its benchmark.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
39 minutes ago
- South China Morning Post
China's firms invest more efficiently when facing ‘trade shocks': researchers
Chinese firms tend to invest more efficiently when facing higher duties or import restrictions, according to a study that highlights an unexpected benefit of tariffs by analysing data from before the two trade wars with the United States. Published in the peer-reviewed Journal of Corporate Finance, the paper examined more than 2,700 listed firms in China, their financial and accounting data from 2003 to 2016, and the trade barriers imposed on the country during this period. The paper was released in April when Chinese exporters faced renewed trade turbulence, with the world's two largest economies imposing triple-digit tariffs on each other – before agreeing to a 90-day truce in May. The European Union has also levied anti-subsidy duties on Chinese electric vehicles. Trade defence instruments (TDIs), such as anti-dumping or countervailing duties, have largely prompted Chinese companies to allocate capital more effectively, according to the paper. This was especially true for cash-rich firms that lacked strong governance, where unchecked investments had been more common. 'Our findings reveal a nuanced dynamic, showing that trade protection measures, such as TDIs, can have complex and counterintuitive effects on target firms' resource allocation and the broader economy.' The authors called trade shocks an 'external disciplining mechanism' that reduces free cash flow and curbs overinvestment, where excessive resources are poured into underperforming projects.
South China Morning Post
an hour ago
- South China Morning Post
More investor attention coming to China advancements in AI, humanoid tech: Morgan Stanley
China's advancements in artificial intelligence (AI) and humanoid technology will continue to capture the imaginations of investors as the world turns its focus to the region, according to Morgan Stanley 's director of pan-Asia research. Advertisement 'The DeepSeek announcement has shifted the fundamental discussion about China to technological innovation,' said Magdalena Stoklosa in an interview last month. 'This theme is multi-year and incredibly important.' Her team identified technological diffusion and the spread of AI across economies as key long-term research themes. AI start-up DeepSeek's breakthroughs earlier this year in large-language models sparked a rally in Chinese stocks. In February, the US investment bank upgraded Chinese stocks to equal weight from underweight, due to improving valuations and a significant shift towards new-economy companies. 'We still see that China is underweight from a perspective of global emerging markets positioning and it should effectively be at least close,' Stoklosa said. Advertisement Over the next 12 to 18 months, she said it was important to keep an eye on how various AI models work, spread through the economy and become monetised. 'In China, the discussion is layered with government support for AI infrastructure, a thriving innovation scene with start-ups, mega industry players, and a strategic push to build open-source models that make access to AI quicker and more affordable for many corporations,' she added.
South China Morning Post
an hour ago
- South China Morning Post
Mainland Chinese market for weight loss and diabetes drugs to soon be more crowded: report
Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after Denmark-based Novo Nordisk's semaglutide product loses patent protection in China next year, according to Boston-based global consultancy L.E.K. Consulting. Novo Nordisk's patent will expire in 2031 in Japan and Europe and 2032 in the US, according to its latest annual report. 'The landscape in China is expected to become even more competitive than in developed markets, where the GLP-1 category is primarily dominated by leading multinational pharmaceutical companies,' said Helen Chen, L.E.K.'s global healthcare and life sciences co-head, in a report on May 15. GLP-1 drugs mimic natural hormones, which signal the pancreas to release more insulin when blood-sugar levels are high, and also support weight loss by slowing digestion and reducing appetite. 04:12 One reporter's weight-loss journey and what a 'healthy body' means to him One reporter's weight-loss journey and what a 'healthy body' means to him Driven by sales growth of semaglutide, Novo Nordisk became the 10th largest drug company in the world in terms of revenue. London-based consultancy Evaluate said the firm's revenue rose 25 per cent to US$42.1 billion last year.
